BR0012688A - Novos peptìdios - Google Patents

Novos peptìdios

Info

Publication number
BR0012688A
BR0012688A BR0012688-8A BR0012688A BR0012688A BR 0012688 A BR0012688 A BR 0012688A BR 0012688 A BR0012688 A BR 0012688A BR 0012688 A BR0012688 A BR 0012688A
Authority
BR
Brazil
Prior art keywords
amino acid
new peptides
compound
activity
replaced
Prior art date
Application number
BR0012688-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Kenji Kangawa
Masayasu Kojima
Hiroshi Hosoda
Hisayuki Matsuo
Yoshiharu Minamitake
Original Assignee
Kenji Kangawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenji Kangawa filed Critical Kenji Kangawa
Publication of BR0012688A publication Critical patent/BR0012688A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR0012688-8A 1999-07-23 2000-07-24 Novos peptìdios BR0012688A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP21000299 1999-07-23
JP33884199 1999-11-29
JP2000126623 2000-04-26
PCT/JP2000/004907 WO2001007475A1 (en) 1999-07-23 2000-07-24 Novel peptides

Publications (1)

Publication Number Publication Date
BR0012688A true BR0012688A (pt) 2002-04-16

Family

ID=27329078

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0012688-8A BR0012688A (pt) 1999-07-23 2000-07-24 Novos peptìdios
BRPI0012688A BRPI0012688B8 (pt) 1999-07-23 2000-07-24 método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0012688A BRPI0012688B8 (pt) 1999-07-23 2000-07-24 método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas

Country Status (16)

Country Link
US (5) US7385026B1 (enExample)
EP (3) EP2119785B1 (enExample)
JP (2) JP3471780B2 (enExample)
KR (1) KR100827973B1 (enExample)
CN (2) CN101693736B (enExample)
AT (2) ATE366813T1 (enExample)
AU (2) AU784035B2 (enExample)
BR (2) BR0012688A (enExample)
CA (2) CA2696819C (enExample)
CY (2) CY1107724T1 (enExample)
DE (2) DE60035502T2 (enExample)
DK (2) DK1197496T3 (enExample)
ES (3) ES2288151T3 (enExample)
IL (2) IL147652A0 (enExample)
PT (2) PT1197496E (enExample)
WO (1) WO2001007475A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101693736B (zh) * 1999-07-23 2020-09-11 寒川贤治 新的肽
AU1925701A (en) * 1999-11-22 2001-06-04 Zymogenetics Inc. Method of forming a peptide-receptor complex with zsig33
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
DE60135985D1 (de) 2000-05-12 2008-11-13 Kaneka Corp Verfahren zur reinigung von vinylpolymer
CA2411667A1 (en) 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
CN1443198A (zh) * 2000-07-24 2003-09-17 阿达纳生物科学有限公司 Ghrelin拮抗剂
US7138489B2 (en) 2002-04-11 2006-11-21 Daiichi Asubio Pharma Co., Ltd. Method for producing a modified peptide
IL162796A0 (en) * 2002-05-21 2005-11-20 Kenji Kangawa Medicinal compositions containing ghrelin
US20040076645A1 (en) * 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates
RU2373220C2 (ru) * 2002-07-23 2009-11-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Аналоги грелина
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
NZ539218A (en) * 2002-09-18 2008-03-28 Univ Montreal Ct Hospitalier Chum Synthetic GHRH analogues of 29 amino acids or more
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
US10653637B2 (en) 2003-04-30 2020-05-19 Kenji Kangawa Preventives or remedies for hepatopathy
WO2005016951A2 (en) * 2003-06-04 2005-02-24 Eli Lilly And Company Anti-ghrelin fab antibodies
WO2005026211A2 (en) * 2003-09-05 2005-03-24 Eli Lilly And Company Anti-ghrelin antibodies
CN1321131C (zh) * 2003-12-26 2007-06-13 李宁 猪Ghrelin衍生物及其编码基因与应用
KR20060128924A (ko) * 2004-01-20 2006-12-14 사이토스 바이오테크놀로지 아게 그레린-담체 접합체
US7026175B2 (en) 2004-03-29 2006-04-11 Applied Materials, Inc. High throughput measurement of via defects in interconnects
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
CA2603295A1 (en) * 2004-04-07 2006-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism
WO2005097830A2 (en) * 2004-04-07 2005-10-20 Aditech Pharma Ab Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
EP1750745A1 (en) * 2004-05-11 2007-02-14 The United States of America, represented by the Secretary, Department of Health and Human Services Methods of inhibiting proinflammatory cytokine expression using ghrelin
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
EP1776386A1 (en) * 2004-07-14 2007-04-25 Eli Lilly And Company Anti-ghrelin antibodies
WO2006045319A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
JP2008521840A (ja) * 2004-11-30 2008-06-26 ガストロテック・ファルマ・アクティーゼルスカブ 成長ホルモン分泌促進物質レセプター１ａリガンド
KR101295104B1 (ko) 2005-02-23 2013-08-09 다이이찌 산쿄 가부시키가이샤 췌장 β 세포의 재생 촉진제 및 췌장 β 세포의 인슐린생산 촉진제
EP1856154A1 (en) 2005-02-23 2007-11-21 Eli Lilly And Company Humanized anti-ghrelin antibodies
RU2427587C2 (ru) * 2005-09-28 2011-08-27 Ипсен Фарма С.А.С. Аналоги грелина
PT1937262T (pt) 2005-09-29 2019-08-21 Ipsen Pharma Sas Composição para utilização no tratamento de dismotilidade gastrointestinal
BRPI0618824A2 (pt) * 2005-11-21 2011-09-13 Univ Miyazaki agente terapêutico acelerador de recuperação dérmica contendo grelina e derivados desta ou substáncias que atuam sobre ghs-r1a como ingrediente ativo
AU2006316101A1 (en) * 2005-11-21 2007-05-24 Daiichi Sankyo Company, Limited Therapeutic agent for skin or skin repair-promoting agent comprising des-acylghrelin or derivative thereof as active ingredient
US20100227806A1 (en) * 2006-03-10 2010-09-09 Tulipano Giovanni Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
BRPI0708895A2 (pt) 2006-03-13 2011-06-28 Liat Mintz uso de variante de junção de grelina para tratar caquexia e/ou anorexia e/ou anorexia-caquexia e/ou subnutrição e/ou lipodistrofia e/ou atrofia muscular e/ou estimulação do apetite
EA200970166A1 (ru) * 2006-08-01 2009-06-30 Дзе Скриппс Рисерч Инститьют Вакцины и способы для регуляции ожирения
BRPI0715809A2 (pt) 2006-08-11 2014-11-25 Univ Miyazaki Agente terapêutico para a aceleração da restauração do nervo espinhal compreendendo grelina, seus derivados ou substâncias capazes de atuar sobre o ghs-r1a como ingrediente ativo.
WO2008018597A1 (fr) * 2006-08-11 2008-02-14 University Of Miyazaki Agent thérapeutique permettant d'accélérer la réparation des nerfs rachidiens comprenant en tant que matière active de la désacyl ghréline ou un dérivé de celle-ci
EP2083842B1 (en) 2006-09-27 2013-08-28 Ipsen Pharma S.A.S. Analogs of ghrelin substituted at the n-terminal
HRP20160303T1 (hr) 2008-05-23 2016-04-22 Daiichi Sankyo Company, Limited Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
CA2761901C (en) * 2009-05-12 2019-08-13 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
JP6057314B2 (ja) 2010-01-15 2017-01-11 国立大学法人 宮崎大学 加療中動物の回復促進治療剤
AU2011268256B8 (en) 2010-06-16 2016-12-22 Mcgill University Growth hormone secretatogue receptor antagonists and uses thereof
US9555077B2 (en) 2011-03-03 2017-01-31 University Of Miyazaki Methods of lowering body temperature by administration of desacyl ghrelin or its derivative
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
JP6218084B2 (ja) 2012-10-04 2017-10-25 国立研究開発法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CA2889499C (en) 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
WO2014119753A1 (ja) * 2013-01-31 2014-08-07 学校法人 東京薬科大学 マイオスタチン阻害ペプチド
US9682126B2 (en) * 2013-03-25 2017-06-20 Zeria Pharmaceutical Co., Ltd. Postprandial gastrokinetic agent
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
CN109879935B (zh) * 2019-03-04 2020-11-20 南京工业大学 一种多肽的液相合成方法
JP7725466B2 (ja) 2019-11-13 2025-08-19 アムニクス ファーマシューティカルズ， インコーポレイテッド バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN120818010B (zh) * 2025-09-18 2025-12-05 天津科技大学 一种来自植物乳杆菌属细胞外囊泡的短肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
JP3712261B2 (ja) * 1992-04-07 2005-11-02 ザ スクリップス リサーチ インスティテュート 修飾タンパク質の製造方法
JPH11502844A (ja) * 1995-03-31 1999-03-09 アメリカン・サイアナミド・カンパニー 成長促進特性を持つペプチド
IL118473A0 (en) 1995-06-02 1996-09-12 Suntory Ltd Staphylococcus aureus V8 protease genes coding therefor and a method for the production thereof
JP3982866B2 (ja) 1996-03-04 2007-09-26 アスビオファーマ株式会社 分泌型Ｋｅｘ２誘導体の製造方法
CA2198966C (en) 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
CA2284733C (en) * 1997-03-24 2010-10-26 Zymogenetics, Inc. Motilin homologs
CA2328895A1 (en) 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN1120846C (zh) * 1999-02-13 2003-09-10 中国人民解放军军事医学科学院基础医学研究所 生长激素释放肽及其应用
US6420521B1 (en) * 1999-06-30 2002-07-16 Zymogenetics, Inc. Short gastrointestinal peptides
CN101693736B (zh) 1999-07-23 2020-09-11 寒川贤治 新的肽

Also Published As

Publication number Publication date
DE60035502D1 (de) 2007-08-23
CA2380058A1 (en) 2001-02-01
EP1197496A1 (en) 2002-04-17
CA2696819A1 (en) 2001-02-01
ATE449174T1 (de) 2009-12-15
US20100240866A1 (en) 2010-09-23
ES2288151T3 (es) 2008-01-01
PT1197496E (pt) 2007-08-29
JP3471780B2 (ja) 2003-12-02
AU2006201580B2 (en) 2009-01-08
AU2006201580A1 (en) 2006-05-18
ATE366813T1 (de) 2007-08-15
DE60043361D1 (de) 2009-12-31
ES2401939T3 (es) 2013-04-25
EP2119785A1 (en) 2009-11-18
US20090170763A1 (en) 2009-07-02
CA2380058C (en) 2011-08-09
BRPI0012688B1 (pt) 2018-06-05
CY1109714T1 (el) 2014-08-13
JP2004000251A (ja) 2004-01-08
US9938332B2 (en) 2018-04-10
EP1197496B1 (en) 2007-07-11
EP1197496A4 (en) 2002-11-20
EP1197496B8 (en) 2007-10-03
US9573986B2 (en) 2017-02-21
BRPI0012688B8 (pt) 2021-05-25
CN1362968A (zh) 2002-08-07
DE60035502T2 (de) 2008-03-20
US8524871B2 (en) 2013-09-03
US8227570B2 (en) 2012-07-24
DK1197496T3 (da) 2007-10-22
US7385026B1 (en) 2008-06-10
KR20020026543A (ko) 2002-04-10
AU6023100A (en) 2001-02-13
IL147652A0 (en) 2002-08-14
WO2001007475A1 (en) 2001-02-01
DK1795598T3 (da) 2010-02-01
KR100827973B1 (ko) 2008-05-21
CN101693736A (zh) 2010-04-14
EP2119785B1 (en) 2013-03-13
CY1107724T1 (el) 2013-04-18
PT1795598E (pt) 2010-01-05
IL147652A (en) 2010-04-29
CN100506844C (zh) 2009-07-01
CN101693736B (zh) 2020-09-11
JP4227857B2 (ja) 2009-02-18
EP1795598A1 (en) 2007-06-13
AU784035B2 (en) 2006-01-19
US20110184153A1 (en) 2011-07-28
US20130172251A1 (en) 2013-07-04
ES2335235T3 (es) 2010-03-23
CA2696819C (en) 2015-07-07
EP1795598B1 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
DK1197496T3 (da) Hidtil ukendte peptider
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
AU2001272735A1 (en) Novel physiologically active peptide and use thereof
ATE446758T1 (de) Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
PE20030895A1 (es) Cis-imidazolinas
HUP9701059A2 (hu) Stronciumsók alkalmazása ízületi bántalmak kezelésére alkalmas gyógyszerkészítmények előállítására
ATE155486T1 (de) Zyklische peptide und ihre verwendung
ATE497390T1 (de) Neue therapeutische verwendung von smr-1 peptide
DE69841267D1 (de) Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
DE60231649D1 (de) Mittel zur behandlung von augentrockenheit und damit zusammenhängenden erkrankungen
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
DE69722610D1 (de) Neue Inhalationspräparate enthaltend CR 2039 (Andolast)
MXPA04000775A (es) Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
WO2002062944A2 (en) Novel physiologically active peptide and use thereof
AU2003202489A1 (en) Screening method
WO2003022300A1 (en) Preventives/remedies for bone/joint diseases
WO2001019358A3 (en) Use dexrazoxane for treating psoriasis
BR9711960A (pt) Verapamil como um medicamento para o tratamento de angina
CY1106694T1 (el) Σουλφοναμιδια και παραγωγα αυτων που ρυθμιζουν τη δραστικοτητα ενδοθηλινης
YU17002A (sh) Upotreba deksrazoksana u lečenju psorijaze
NO20023783D0 (no) Partnere av PTB 1-domene av FE65, fremstilling og anvendelse derav
HUP0203173A2 (hu) Metformint és N-[2-hidroxi-3-(1-piperidinil)-propoxi]-piridin-1-oxi-3-karboximidoil-kloridot tartalmazó kombinált hatóanyagos gyógyászati készítmény

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O REQUERENTE DEVERA APRESENTAR O ARQUIVO NO FORMATO TXT E A DECLARACAO IMPRESSA CONFORME A RESOLUCAO 70/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/07/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/07/2020